Form 4: Minerva Neurosciences Director Receives Stock Options

Director Hans Peter Hasler was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of his compensation.

Summary

• Director Hans Peter Hasler received a grant of 50,000 stock options on June 3, 2026.
• The options have an exercise price of $4.68 per share.
• The options are set to expire on June 2, 2036.
• The grant vests in four equal quarterly installments starting three months after the grant date, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the continued service of the director, creating a dependency on personnel retention.

Future Outlook

The options vest over a one-year period in quarterly installments, assuming continued service as a non-employee director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotechnology firms.
• The vesting schedule of one year is relatively aggressive compared to some industry peers who may utilize three-to-four-year vesting periods.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Quarterly vesting of options beginning September 2026.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, Director Compensation, Stock Options, Insider Transaction